Tradestie Institutional Equity Comparison Engine

ANNX vs NUVB โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ANNX Overall Edge

ANNX Captures Institutional Edge (3โ€“0 Pillars ยท 2โ€“6 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Annexon, Inc. Common Stock (ANNX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ANNX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus NUVB at N/M Forward P/E and -61.2% operating margin (+242.6% YoY). In options structure, ANNX sits in BREAKDOWN (24th %ile IV; Dealer Gamma Walls on Pro) against NUVB sits in BREAKDOWN (26th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ANNX N/M vs NUVB N/M Fwd P/E
Growth & Margin Winner ANNX
Op Margin 0.0% vs -61.2% ยท YoY +0.0% vs +242.6%
Momentum & Technical Winner ANNX
1Y -23.6% vs -46.9% ยท 52W Pos 1% vs 2%
Options & Structure Winner ANNX
BREAKDOWN (24th %ile IV) vs BREAKDOWN (26th %ile IV)
ANNX NASDAQ
Annexon, Inc. Common Stock
Pharmaceutical Preparations
$3.10
-9.09% 1D
Market Cap $650.5M
1M Return -18.64%
1Y Return -23.65%
Forward P/E N/M
Unified AI Score
38.6 / 100 SELL
Tech 25.0 Fund 50.0 Flow 71.0 Mom 55.0
NUVB NYSE
Nuvation Bio Inc.
Pharmaceutical Preparations
$3.80
-0.26% 1D
Market Cap $1.3B
1M Return -19.15%
1Y Return -46.85%
Forward P/E N/M
Unified AI Score
61.0 / 100 BUY
Tech 53.0 Fund 61.0 Flow 67.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ANNX -23.65% NUVB -46.85% Spread: +23.2 pp (ANNX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ANNX TTM Op. Margin: 0.0% NUVB TTM Op. Margin: -61.2%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANNX vs NUVB. Trailing 12-month operating profitability (ANNX 0.0% vs NUVB -61.2%) and valuation multiples (ANNX N/M vs NUVB N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ANNX (2) vs NUVB (6)
Institutional Metric ANNX NUVB Criterion Row Winner
Market Capitalization Scale $650.5M $1.3B Larger Scale NUVB
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +242.6% Higher Growth NUVB
Operating Margin (TTM) Profitability 0.0% -61.2% Higher Margin ANNX
Net Profit Margin Profitability 0.0% -67.4% Higher Margin ANNX
Return on Equity (ROE) Capital Efficiency -130.8% -49.1% Higher ROE NUVB
52-Week Range Position Momentum 1% ($3โ€“$7) 2% ($4โ€“$10) Stronger Trend NUVB
Beta / 30D Volatility Risk Regime 1.67ฮฒ ยท 66% Vol 1.52ฮฒ ยท 55% Vol Lower Realized Risk NUVB
Unified Institutional Score Composite Signal 38.6 / 100 (SELL) 61.0 / 100 (BUY) Higher Composite NUVB

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ANNX vs NUVB Buy Guide
ANNX BREAKDOWN
91d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 24th %ile
IV Regime Compressed (<25th %ile)
Live ANNX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
NUVB BREAKDOWN
105d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 26th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live NUVB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ANNX nor NUVB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.